Lars Holmgren's Group
The research group of Lars Holmgren has focused its efforts into understanding the mechanisms by which blood vessels are established.
Our research niche is the discovery of the angiomotin family of proteins that play distinct roles during de novo vascularization. Recently, we have also provided evidence that the Amot family plays an important role during tumorigenesis as well. Our overall goal is to understand the molecular pathways involved in the formation of functional vessels and other tube forming organs and to target these pathways in cancer.
Our research focuses on the development of radiopharmaceuticals for precision diagnostics, therapy and monitoring of diseases, with the emphasis in oncological diseases. We conduct studies including cyclotron production of exotic radiometals using solid target, novel radiotracer developments, and biological evaluation studies in vitro and in vivo to clinical translation.
Novel targeted therapies in cancer to overcome drug resistance